| Patent Number |
Title Of Patent |
Date Issued |
| 6669946 |
METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL |
December 30, 2003 |
| The invention relates to complexes of human leukocyte antigen molecules and tyrosinase derived peptides SEQ ID NO: 2, on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention. |
| 6284476 |
Method of identifying individuals suffering from a cellular abnormality some of whose abnormal c |
September 4, 2001 |
| The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The diagnostic ramifications of this observation are the subject of the invention. |
| 6201111 |
Methods for treating subjects with disorders characterized by expression of tumor rejection anti |
March 13, 2001 |
| The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discove |
| 6001975 |
Precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
December 14, 1999 |
| The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discove |
| 5856091 |
Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at le |
January 5, 1999 |
| The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discove |
| 5854203 |
Tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by |
December 29, 1998 |
| The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discove |
| 5843688 |
Isolated tyrosinase derived peptides and uses thereof |
December 1, 1998 |
| The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention. |
| 5843687 |
Isolated, tyrosinase derived peptides and uses thereof |
December 1, 1998 |
| The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention. |
| 5837476 |
Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen prec |
November 17, 1998 |
| The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discove |
| 5747271 |
Method for identifying individuals suffering from a cellular abnormality some of whose abnormal |
May 5, 1998 |
| The invention relates to the identification of complexes of HLA-A2 and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention. |
| 5620886 |
Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at le |
April 15, 1997 |
| The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discove |
| 5530096 |
Isolated, tyrosinase derived peptides and uses thereof |
June 25, 1996 |
| The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention. |
| 5519117 |
Isolated, tyrosinase derived peptides and uses thereof |
May 21, 1996 |
| The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention. |
